Prosecution Insights
Last updated: April 19, 2026

BIONOXX INC.

4 pending office actions

Portfolio Summary

4
Total Pending OAs
3
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18281884 VIRAL VECTOR-DERIVED TARGET PROTEIN FOR ANTICANCER THERAPY AND BINDING MOLECULE OR FRAGMENT THEREOF SPECIFICALLY BINDING THERETO DRISCOLL, LORA E BARNHART 3991 Non-Final OA Sep 13, 2023
17798131 PHARMACEUTICAL COMPOSITION FOR INHIBITING INFLAMMATORY RESPONSE COMPRISING HYDROXYUREA CORNET, JEAN P 1628 Final Rejection Aug 08, 2022
17638144 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING ANTICANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS DENT, ALANA HARRIS 1643 Final Rejection Feb 24, 2022
17638143 PHARMACEUTICAL COMPOSITION COMPRISING VACCINIA VIRUS AND HYDROXYUREA AS ACTIVE INGREDIENT FOR TREATMENT OF CANCER ALAM, DANYAL HASSAN 1671 Final Rejection Feb 24, 2022

Managing BIONOXX INC.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month